ArticleBiomedical chromatography : BMC2025
Serum Metabolomics of Patients with Hepatic Cystic Echinococcosis.
Article in Biomedical chromatography : BMC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolomic Biomarkers for the Human Diagnosis of Neglected Tropical Diseases: A Systematic Review.Revista da Sociedade Brasileira de Medicina Tropical · 2026Pooled it
- Serum Metabolomics of Patients with Hepatic Cystic Echinococcosis.Biomedical chromatography : BMC · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatic cystic echinococcosis (HCE), a liver manifestation of hydatid disease, is among the 17 neglected tropical diseases (NTDs) prioritized by the WHO for eradication by 2025. Although imaging and serological tests are currently the main diagnostic approaches for HCE, they have notable limitations in sensitivity and specificity. Here, we applied liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based metabolomic profiling to uncover differential metabolites and highlight disrupted metabolic pathways, aiming to identify candidate biomarkers for HCE diagnosis. Ten patients diagnosed with HCE were enrolled in the case group. Thirteen healthy individuals were included as controls. Serum metabolomic profiling was performed using LC-MS/MS. Differences in metabolite profiles between the two groups were analyzed employing both univariate and multivariate statistical methods. A total of 20 differential metabolites were significantly altered in the HCE group compared to the controls (p < 0.05, VIP > 1.0). Pathway and enrichment analyses revealed that these metabolites were mainly involved in 8 metabolic pathways, suggesting their potential as candidate biomarkers for HCE diagnosis. These findings enhance our understanding of the metabolic alterations associated with HCE and provide a foundation for further investigation into the disease's pathogenesis and the development of metabolite-based diagnostic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.